Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX Vaccine for Advanced MDS/AML Post-Transplant
NCT01773395Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2013
- Primary completion
- Dec 2020
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) comparing GVAX with Placebo (2 arms). Primary endpoint: Progression Free Survival at 18 months. Started Jan 2013; status: terminated.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01773395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773395.